Montefiore Einstein Comprehensive Cancer Center

Recent papers from Montefiore Einstein Comprehensive Cancer Center

1. Phosphatidylserine receptors are critical for lethal infection by Crimean-Congo hemorrhagic fever virus2026
2. Peginterferon alfa-2a, bictegravir-emtricitabine-tenofovir alafenamide, and venetoclax in adult T-cell leukemia/lymphomaBlood · 2026
3. Integration of Tobacco-Cessation Interventions into Tuberculosis and HIV CareNew England Journal of Medicine · 2025
4. Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025Cancer · 2026
5. Exploiting an epigenetic resistance mechanism to PI3-kinase inhibition in leukemic stem cellsLeukemia · 2026
6. Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancerJournal for ImmunoTherapy of Cancer · 2026
7. Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemiaBlood Neoplasia · 2026
8. Machine learning–based identification of patients at risk for early infectious complications after CAR-T in multiple myeloma.Journal of Clinical Oncology · 2026
9. Demographic and molecular landscape of biliary tract cancers in and near Bronx, NY.Journal of Clinical Oncology · 2026
10. Safety and efficacy of BAL0891 as monotherapy and in combination with paclitaxel: Results from a phase I study in advanced solid tumors.Journal of Clinical Oncology · 2026
11. Clinical outcomes of ethnically and racially diverse patients with gynecologic malignancies in phase I clinical trials at a single institution (2021–2024).Journal of Clinical Oncology · 2026
12. Validation of melanoma immune profile (MIP) to predict RFS in stage II-III melanoma on adjuvant interferon trial (E1697).Journal of Clinical Oncology · 2026
13. Implementation of a telephone genetic screening program in breast cancer survivorship in the Bronx: A health care delivery quality improvement project.Journal of Clinical Oncology · 2026
14. Impact of earlier time of first cycle immunotherapy administration on progression-free survival in real-world metastatic non–small cell lung cancer.Journal of Clinical Oncology · 2026
15. A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101).Journal of Clinical Oncology · 2026
16. Advancing value-based breast cancer screening in a safety-net health system: A multimodal approach to improving population health and system sustainability.Journal of Clinical Oncology · 2026
17. Real-world impact of first immunotherapy infusion timing on outcomes in locally advanced non-small cell lung cancer.Journal of Clinical Oncology · 2026
18. Retrospective assessment of Duffy-Null associated neutrophil counts (DANC) status and impact on treatment among patients with and without cancer in an urban academic medical center.Journal of Clinical Oncology · 2026
19. Survival outcomes of human epidermal growth factor receptor 2 (HER2)–amplified and HER2-mutated left-sided colorectal cancer (CRC) patients treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).Journal of Clinical Oncology · 2026
20. Final results of Alliance A031902: A phase III trial of enzalutamide plus rucaparib as first-line therapy in metastatic castration-resistant prostate cancer (CASPAR).Journal of Clinical Oncology · 2026